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Background. Aspergillus polymerase chain reaction (PCR) was excluded from the European Organisation for
the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) deﬁnitions of invasive fungal disease
because of limited standardization and validation. The deﬁnitions are being revised.
Methods. A systematic literature review was performed to identify analytical and clinical information available
on inclusion of galactomannan enzyme immunoassay (GM-EIA) (2002) and β-D-glucan (2008), providing a min-
imal threshold when considering PCR. Categorical parameters and statistical performance were compared.
Results. When incorporated, GM-EIA and β-D-glucan sensitivities and speciﬁcities for diagnosing invasive as-
pergillosis were 81.6% and 91.6%, and 76.9% and 89.4%, respectively. Aspergillus PCR has similar sensitivity and
speciﬁcity (76.8%–88.0% and 75.0%–94.5%, respectively) and comparable utility. Methodological recommendations
and commercial PCR assays assist standardization. Although all tests have limitations, currently, PCR is the only test
with independent quality control.
Conclusions. We propose that there is sufﬁcient evidence that is at least equivalent to that used to include
GM-EIA and β-D-glucan testing, and that PCR is now mature enough for inclusion in the EORTC/MSG deﬁnitions.
Keywords. Aspergillus; PCR; galactomannan; β-D-glucan; aspergillosis.
Polymerase chain reaction (PCR) to aid diagnosis of
invasive aspergillosis (IA) has been used for over 2 de-
cades, but is not included in the European Organisation
for the Research and Treatment of Cancer/Mycoses
Study Group (EORTC/MSG) deﬁnitions of invasive
fungal disease. In the 2002 deﬁnitions, PCR was excluded
on the basis of potential false-positive results and lack of
standardized commercial testing platforms [1]. It was re-
considered when the deﬁnitions were revised in 2008, but
despite continued development, molecular methods were
not to be included because there was no standard; and
clinically, validation was limited [2].
The EORTC/MSG deﬁnitions are currently under re-
view. To provide impartial review ofAspergillus PCR tech-
nology, we reassessed information that was available at the
time of inclusion of previous biomarkers, galactomannan
enzyme immunoassay (GM-EIA) in 2002, and β-D-glucan
(BDG) in 2008. This baseline information provides a sys-
tematic dataset for categorical and standardized compari-
son of PCR, and any other emerging or future diagnostic
assays (eg, Aspergillus lateral ﬂow device; [3, 4]. The
evidence forms the basis for full review of manuscripts de-
scribing Aspergillus PCR allowing the EORTC/MSG con-
sensus committee to consider PCR in future deﬁnitions.
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This manuscript describes the ﬁndings of this initial review
and is a joint effort of the European Aspergillus PCR initiative
(EAPCRI), a working group of the International Society for
Human and Animal Mycology, the EORTC Infectious Disease
Group, and the Mycoses Study Group (MSG).
REVISION PROCESS
Evaluating the GM-EIA and BDG Evidence Available Prior to
Incorporation Into Disease Deﬁnitions
Manuscripts describing the use of GM-EIA and BDG were
identiﬁed by literature searches using Medline/PubMed
using the following keywords: Aspergillus diagnosis, galacto-
mannan EIA or ELISA [enzyme-linked immunosorbent
assay], Aspergillus antigen, aspergillosis for GM-EIA, glucan,
β-glucan, fungal infection (diagnosis), mycoses, Aspergillus
for BDG. To conﬁrm the quality of the literature searches
and identify missed articles, bibliographies of representative
meta-analyses were screened [5–12]. Only manuscripts pub-
lished before incorporation of both assays into the EORTC/
MSG deﬁnitions were included.
The focus of studies was determined by reviewing the title
and abstract. If the study was a technical description or an an-
imal model evaluation, it was assessed for any potential useful
information (eg, cross-reactivity with other fungal species, in-
terassay reproducibility, or potential kinetics of antigen release)
but excluded from performance analysis. For clinical evaluation,
factors deemed important with respect to diagnostic use were
identiﬁed (Table 1). As the BDG assay detects a broader range
of fungi, performance data speciﬁc to the detection of IA were
retrieved from the original manuscript, and manuscripts were
excluded if this was not possible.
Evaluating the Evidence Base for Aspergillus PCR Testing
Manuscripts describing the use of PCR were identiﬁed by liter-
ature searches using PubMed. More than 200 manuscripts were
available for review [13, 14].Many were available before the last
EORTC/MSG revision, so the focus was on important develop-
ments in the ﬁeld of Aspergillus PCR, particularly after 2008.
Relevant meta-analyses were used, representing an independent
and statistically sound representation of clinical performance
[15–19].
Statistical Analysis
Sensitivity, speciﬁcity, positive and negative predictive values,
likelihood ratios, and diagnostic odds ratios were calculated.
Prospective and retrospective studies were analyzed both sepa-
rately and combined. The 95% conﬁdence intervals (CIs) were
calculated for proportions, and when comparing parameters
between different assays, Fisher exact test was used to generate
a 2-sided P value, with a value of ≤.05 deemed signiﬁcant.
EVIDENCE FOR ANTIGEN TESTING
GM-EIA: Manuscript Characteristics
Sixty-one articles were retained for further review. Sixteen were
subsequently excluded as they did not describe the use of the
BioRad GM-EIA or a precursor of this test (eg, latex agglutina-
tion or in-house ELISA tests). A breakdown of the remaining
manuscripts is shown in Supplementary Figure 1.
GM-EIA: Analytical Evidence
Six manuscripts evaluated GM-EIA detection and provided in-
formation pertinent to clinical performance. Cross-reactivity
with non-Aspergillus fungal species was determined (Supple-
mentary Table 1) [20]. Of greater concern was the generation
of false-positive results (8/40) associated with bacteremia and
candidemia in febrile neutropenic patients [20].
Intra and interassay reproducibility of the GM-EIA was
investigated. Although the qualitative agreement (positive/
negative) between centers was excellent, the quantitative inter-
assay precision was only 25.6% [21].
GM-EIA: Preinclusion Clinical Performance
Of the 26 articles describing clinical performance, 17 were pro-
spective validations. Fifteen of the prospective studies described
the performance of testing serum from 2067 adults with an IA
incidence of 13.9% [22–36]. Six of the retrospective studies de-
scribed performance testing serum from 214 adults with an IA
incidence of 25.7% [37–42]. Neither sensitivity nor speciﬁcity
differed signiﬁcantly between prospective or retrospective stud-
ies (P = .57 and P = .45, respectively). The performance of
serum GM-EIA preincorporation into the EORTC/MSG deﬁni-
tions is summarized in Table 2.
Three studies described the use of GM-EIA in 458 pediat-
ric patients, with an IA incidence of 5.5% [25, 43, 44]. The
pooled sensitivity and speciﬁcity were 100% (95% CI,
86.7%–100%) and 90.1% (95% CI, 86.8%–93.2%), respective-
ly. The testing of bronchoalveolar lavage (BAL) samples was
limited, with pooled sensitivities and speciﬁcities of 89.5%
(95% CI, 68.6%–97.1%) and 93.3% (95% CI, 81.4%–97.6%),
respectively [31, 42]. Evidence for GM-EIA testing of cere-
brospinal ﬂuid was limited to case reports or small series
[35, 45–48].
Characteristics and Clinical Utility of GM-EIA Before 2002
A summary of GM-EIA characteristics is described in Table 1.
Methodological standardization was evident, as only one com-
mercial assay was available. However, since the original
EORTC-MSG deﬁnitions, the analytical threshold for positivity
has been reduced from an optical density (OD) index of 1.5 to
0.5 [21, 23–24, 49–50]. The choice of optimal threshold will be
deﬁned by the strategy chosen. For highly sensitive screening, a
lower OD index ≤0.5 is preferable, whereas to provide accurate
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Table 1. Assay Characteristics With the Potential to Inﬂuence Diagnostic Utility and Fungal Biomarker Information Available at the Time of Incorporation Into the European
Organisation for the Research and Treatment of Cancer/Mycoses Study Group Deﬁnitions
Characteristic Description GM-EIA (<2002) β-D-Glucan (<2008)
Methodological
standardization
A standard method is available for performing
the assay and interpreting the result.
Single commercial assay with SOP. Four different commercial assays available
utilizing different methods and materials.
Control material Material is available to determine whether the
assay is performing efficiently and individual
experimental runs are valid.
Controls supplied by the manufacturer.
No independent material available.
Controls supplied by the manufacturer.
No independent material available.
Quality control Independent (external) QC schemes are
available to determine performance of assays at
individual centers.
No manufacturer or independent QC available No manufacturer or independent QC available
Clinical validity Assay performance (sensitivity/specificity etc) in defined
cases/controls.
An understanding of the causes of false-positive and
false-negative results.
Good performance when testing serum from
hematology/BMT populations (Table 2) [22–31,
34–38, 40–42].
Limited evaluations for the testing of BAL or CSF
samples, and pediatrics/neonates or CGD, HIV
liver transplant patients [25, 29, 31, 32, 35, 36,
39–47, 93].
False Positives – Yes
False Negatives – Yes
Good clinical performance for the diagnosis of
IA when testing serum/plasma from
hematology patients (Table 2) [51, 53, 55, 57,
58, 60, 62, 63].
Limited evidence for use in other conditions
[58, 59, 63].
False positives – Yes
False negatives – Yes
Clinical utility Assays have been incorporated into strategically constructed
care pathways, and have a direct influence on patient
management and potential effect on local hospital policy.
Limited and often conflicting, with no strategic
studies investigating utility were available.
Limited and often conflicting, with no strategic
studies investigating utility were available.
Abbreviations: BAL, bronchoalveolar lavage; BMT, bone marrow transplantation; CGD, chronic granulomatous disease; CSF, cerebrospinal fluid; GM-EIA, galactomannan enzyme immunoassay; HIV, human
immunodeficiency virus; IA, invasive aspergillosis; QC, quality control; SOP, standard operating procedure.
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diagnosis, speciﬁcity can be improved with a higher OD index
of 1.5. The speciﬁcity of GM-EIA as calculated by both meta-
analyses (including studies using the lower threshold) is signiﬁ-
cantly lower than that calculated for studies performed before
2002 using an OD index ≥1.5 (P < .0001–.0003) (Tables 2 and
3). In both meta-analyses, there was a clear trend of increased
speciﬁcity using an OD index ≥1.5 [7, 8]. The US Food and Drug
Administration has recently selected a higher threshold for positivity
for diagnosing IA in clinical trials (invasive aspergillosis biomarker,
/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM420248.pdf). Alternatively, a variable threshold
for positivity could be used to provide conﬁdence in both ex-
cluding disease and for accurate diagnosis, as recently described
for BAL testing [51].
There were no quality control (QC) programs available to
monitor performance before 2002. Both false-positive and
false-negative results were identiﬁed, but assay speciﬁcity was im-
proved when 2 positive results were required for signiﬁcance, as
recommended by the manufacturer (Table 1 and Supplementary
Table 1).
Twice-weekly testing was strongly advocated, and there was
evidence linking the GM-EIA index to the burden of disease
and prognosis, although poor interassay precision may affect
monitoring of disease progression and response to therapy
[21]. The impact of GM-EIA on patient management was var-
iable; some studies showed positive tests to be an early indicator
of disease, whereas others found only a limited effect on patient
management (Supplementary Table 1). No strategic studies
investigating utility were available.
β-D-Glucan: Manuscript Characteristics
Fifty-three articles were retained for further review. Ten were
excluded, as they were speciﬁc to the diagnosis of invasive can-
didiasis or Pneumocystis jirovecii pneumonia. Forty-three man-
uscripts were retained for detailed review, and a breakdown of
their structure is shown in Supplementary Figure 2.
β-D-Glucan: Analytical Evidence
In an in vitro study, the release of BDG occurred primarily
during logarithmic growth (<24 hours), corresponding with in-
creasing fungal biomass, albeit later than the release of GM [52].
As part of multicenter clinical studies, interlaboratory repro-
ducibility of the BDG assay was shown to be good (r2 = 0.93–
0.99; interassay precision 9.1%), and BDG levels remained
stable, with neither storage duration nor freezing/thawing hav-
ing any measurable effect on performance [53, 54]. The analyt-
ical speciﬁcity of the Fungitec G-Test and Fungitell assays were
conﬁrmed, and cross-reactivity with non-glucans (eg, Xylan,
Galactan) containing the β-1–3 linkage or glucans containing
β-1–4 or β-1–6 linkage was excluded [55, 56]. The reactivity
of the Fungitell assay was determined to be 2.5-fold less than
the Fungitec-G assay, necessitating different analytical thresh-
olds for positivity between assays [55]. There were no studies
comparing the analytical performance of all BDG assays.
β-D-Glucan: Preinclusion Clinical Performance
Thirteen articles including 1423 patients, of whom 143 were
diagnosed with proven/probable IA, were analyzed. Perfor-
mance statistics for the diagnosis of IA are shown in Table 2.
Table 2. Performance of Galactomannan Enzyme Immunoassay and β-D-Glucan When Testing Adult Serum for the Detection of Invasive
Aspergillus Prior to Incorporation Into the European Organisation for the Research and Treatment of Cancer/Mycoses Study Group
Deﬁnitions for Diagnosing Invasive Fungal Disease
Parameter
Assay (Preincorporation Into EORTC/MSG Definitions)
GM-EIA Testing (<2002) β-D-Glucan Testing (<2008)
Overall Prospective Retrospective Overall Prospective Retrospective
Sensitivity
(95% CI)
81.6% (75.6–86.4) 80.8% (74.2–86.1) 85.5% (68.9–94.2) 76.9% (66.7–84.8) 66.1% (53.7–76.7) 85.2% (75.9–91.3)
Specificity
(95% CI)
91.6% (89.9–93.1) 91.8% (90.0–93.3) 89.9% (82.0–94.7) 89.4% (87.0–91.4) 88.9% (86.5–90.9) 90.2% (87.2–92.5)
PPV (95% CI) 63.3% (57.3–69.0) 61.4% (54.8–67.5) 74.6% (58.3–86.2) 44.7% (36.8–52.6) 31.5% (22.1–42.8) 59.5% (47.5–70.5)
NPV (95% CI) 96.6% (95.3–97.5) 96.7% (95.4–97.7) 94.7% (87.8–97.9) 97.2% (95.7–98.2) 97.1% (95.1–98.1) 97.3% (94.5–98.7)
Positive LR 9.8 9.9 8.5 7.2 6.0 8.7
Negative LR 0.2 0.21 0.16 0.3 0.38 0.16
DOR 48.6 47.2 52.5 28.0 15.6 52.9
For galactomannan enzyme immunoassay, a total of 26 studies have been included, involving 2281 patients with an incidence of invasive aspergillosis (IA) of 15.0%,
and a positivity index of 1.5. For β-D-glucan, a total of 13 studies have been included involving 1423 patients with an incidence of IA of 10.0%; patients diagnosed with
other forms of invasive fungal disease have been excluded from the analysis. The positivity threshold varied between assays.
Abbreviations: CI, confidence interval; DOR, diagnostic odds ratio; EORTC/MSG, European Organisation for the Research and Treatment of Cancer/Mycoses Study
Group; GM-EIA, galactomannan enzyme immunoassay; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
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Table 3. Performance of Fungal Biomarker Assays for the Detection of Invasive Aspergillosis as Determined by the Relevant Published Meta-analyses
Assay
GM-EIA β-D-Glucan PCR
Leeflang
[7]a
Pfeiffer
[8]b
Zou
[5]c
Guo
[6]d
Lamoth
[9]e
Karageorgopoulos
[10]f
He
[11]g
Onishi
[12]h
Tuon
[15]i
Sun
[16]j
Avni
[18]k
Mengoli
[17]l
Arvanitis
[19]m
Parameter Serum BAL Plasma/Serum BAL Blood
Sensitivity, % 79.3 79.3 83.6 85.7 56.8 77.1 77.0 77.3 78.4 79.6 76.8 88.0 84.0
Specificity, % 80.5 86.3 89.4 89.0 97.0 85.3 81.3 83.4 93.7 94.1 94.5 75.0 76.0
PPV, % 30.3 46.9 64.4 66.7 55.6 30.2 28.7 33.4 74.1 79.2 79.9 36.7 41.3
NPV, % 97.3 96.5 95.9 96.0 97.1 97.8 97.3 97.2 94.9 94.2 93.4 97.4 95.9
Positive LR 4.06 5.81 7.89 7.81 18.90 5.24 4.12 4.65 12.43 13.38 13.87 3.52 3.50
Negative LR 0.26 0.24 0.18 0.16 0.44 0.27 0.28 0.27 0.23 0.22 0.25 0.16 0.21
DOR 15.8 24.2 43.0 48.6 43.0 19.4 14.7 17.2 53.8 61.7 56.52 22.1 16.6
Abbreviations: BAL, bronchoalveolar lavage; DOR, diagnostic odds ratio; GM-EIA, galactomannan enzyme immunoassay; LR, likelihood ratio; NPV, negative predictive value; PCR, polymerase chain reaction; PPV,
positive predictive value.
a Includes 87 proven/probable invasive aspergillosis (IA) cases and 814 controls where performance was reported using a 0.5 positivity index [7].
b Includes 87 proven/probable IA cases and 571 controls where performance was reported using a 0.5 positivity index [8].
c Includes 493 proven/probable IA cases and 2144 controls where performance was reported using a 0.5 positivity index. The results represent pooled parameters (sensitivity/specificity) and differ from the published
data that were summary estimates as calculated by Summary Receiver Operator Characteristic (SROC) analysis (sensitivity 87% and specificity 89%) [5]. Due to limitations in the reporting of the number of cases and
controls in studies specifically using a 0.5 positivity index, it was not possible to calculate the PPV/NPV from data in the original manuscript. Consequently, PPV/NPV have been calculated using the data from the original
publications, using publications only listed in the meta-analysis of Zou et al [5].
d Includes 133 proven/probable IA cases and 519 controls where performance was reported using a 0.5 positivity index and is based on pooled performance data, not summary estimates as described in the meta-
analysis of Guo et al [6].
e Includes 44 proven/probable IA cases and 653 controls where results are based on pooled performance data [9]. Performance in relation to the detection of other proven/probable fungal etiologies (n = 33) has been
excluded.
f Includes 197 proven/probable IA cases and 2385 controls where results are based on pooled performance data [10]. Performance in relation to the detection of other proven/probable fungal etiologies (n = 352) has been
excluded.
g Includes 322 proven/probable IA cases and 3290 controls, and results are based on pooled performance data [11]. Performance in relation to the detection of other proven/probable fungal etiologies (n = 590) has been
excluded.
h Includes 252 proven/probable IA cases and 2410 controls, and results are based on pooled performance data [12]. Performance in relation to the detection of other proven/probable fungal etiologies (n = 650) has been
excluded.
i Includes 245 proven/probable IA cases and 1063 controls, determined by combining case/control and PCR positivity data as described in Table 2 of the meta-analysis by Tuon [15].
j Includes 263 proven/probable IA cases and 927 controls where performance was reported using a single positive PCR as significant. The results represent pooled parameters (sensitivity/specificity) and differ from the
published data that were summary estimates as calculated by SROC analysis (sensitivity 91% and specificity 92%) [17].
k Includes 319 proven/probable IA cases and 1266 controls where performancewas reported using a single positive PCR as significant. The results represent pooled parameters (sensitivity/specificity) and differ from the
published data that were summary estimates as calculated by SROC analysis (sensitivity 90.2% and specificity 96.4%) [18].
l Includes 230 proven/probable IA cases and 1386 controls where performance was reported using a single positive PCR as significant [16].
m Includes 374 proven/probable IA episodes and 1863 unlikely IA episodes, determined by combining the episode data as described in Table 1 (characteristics of studies) with the final study determination as described
in Table 2 (quality assessment and final determination of inclusion vs exclusion based on QUADAS 2 tool), as published in the meta-analysis of Arvanitis et al [19].
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Seven retrospective studies comprised 560 patients with an IA
incidence of 14.5% [54, 55, 57–60]. Six prospective studies com-
prised 863 patients with an IA incidence of 7.2% [53, 61–65].
The difference between prospective and retrospective sensitivity
was signiﬁcant (P = .0093) (Table 2), although the proportion of
cases tested by the different BDG assays varied between retro-
spective and prospective testing (P = .0287). In retrospective
testing, 54.3% of cases were tested by the Fungitell assay,
compared with 35.5% during prospective testing.
A comparison of performance of various BDG assays for
the detection of IA is shown in Table 4. The sensitivity of the
Fungitell was signiﬁcantly greater than that of the Wako assay
(P = .0469), whereas the speciﬁcity and positive predictive values
of the Wako assay were signiﬁcantly higher than both Fungitec
G-Test and Fungitell assays (P < .0001 and P = .0014, respectively).
All testing was performed on serum or plasma samples, with
no pediatric data available.
Characteristics and Clinical Utility of β-D-Glucan Before 2008
With 4 different commercial assays, available method variability
was evident (Table 1 and Supplementary Table 1). In addition,
positivity thresholds varied and were still to be ﬁnalized for indi-
vidual assays. The BDG assay is capable of detecting a broad
range of fungi, although it is not clear whether a single threshold
for positivity is applicable to all etiologies [66]. No QC programs
were available to monitor performance. Both false-positive and
false-negative results were observed (Supplementary Table 1).
From a strategic viewpoint, twice-weekly testing was strongly
advocated. The utility of BDG positivity on patient manage-
ment was limited; some studies showed it to be an early indica-
tor of disease, whereas others thought it had limited impact on
patient management, although combining its use with other
diagnostics (high resolution computed tomography, GM-EIA
or PCR) could be beneﬁcial (Supplementary Table 1). No stra-
tegic studies investigating utility were available.
EVIDENCE FOR MOLECULAR-BASED ASSAYS
Comparison of Aspergillus PCR With GM-EIA and β-D-Glucan
Methodological Standardization
PCR was excluded from EORTC/MSG deﬁnitions due to the
lack of a standard method and associated clinical validity.
However, overall clinical performance as determined by meta-
analysis of the various methods available is comparable to that
of GM-EIA and BDG (Table 3). Performance aside, standard-
ized methodology provides intra and interassay consistency,
QC, and a standardized approach for the diagnosis of IA.
Over the past decade, national attempts have been made to
standardize fungal PCR [67, 68]. Internationally, the EAPCRI
has, through the distribution of blinded QC panels, identiﬁed
that DNA extraction, not PCR ampliﬁcation, was the critical fac-
tor, and provided recommendations for Aspergillus DNA extrac-
tion from ethylenediaminetetraacetic acid blood, serum, and
plasma [69–71]. Several commercial PCR assays capable of detect-
ing Aspergillus now exist [72–77]. Most provide a standardized
PCR ampliﬁcation system that when combined with EAPCRI rec-
ommendations provide a fully standardized approach.
Control Material
Any commercial PCR assay will provide material to control per-
formance. Additionally, PCR has the advantage of an indepen-
dently developed and internationally standardized Aspergillus
DNA calibrator, used to compare PCR ampliﬁcation performance
between centers [78]. This calibrator could be used to develop an
Table 4. Comparison of the Performance of the Fungitell, Fungitec G-Test, and Wako β-D-Glucan Assays for the Detection of Invasive
Aspergillosis Preinclusion Into the European Organisation for the Research and Treatment of Cancer/Mycoses Study Group Deﬁnitions for
the Diagnosis of Invasive Fungal Disease
Performance Parameter
β-D-Glucan Assay
Fungitell Fungitec G-Test Wako
No. of studies 4 6 3
Total population 527 659 237
Cases of IA (incidence) 66 (12.5%) 45 (6.8%) 32 (13.5)
Sensitivity (95% CI) 82% (70.9–89.3) 80% (66.2–89.1) 63% (42.5–77.1)
Specificity (95% CI) 89% (86.2–91.9) 87% (84.1–89.4) 97% (93.1–98.3)
PPV (95% CI) 52.4 (39.9–64.7) 31.0 (21.1–43.0) 74.1 (48.2–90.2)
NPV (95% CI) 97.2 (94.2–98.7) 98.3 (96.2–99.3) 94.3 (88.6–97.3)
Positive LR 7.70 6.14 18.30
Negative LR 0.20 0.23 0.39
DOR 37.8 26.7 47.1
Abbreviations: CI, confidence interval; DOR, diagnostic odds ratio; IA, invasive aspergillosis; LR, likelihood ratio; NPV, negative predictive value; PPV, positive
predictive value.
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international standard material, permitting comparison of the en-
tire molecular process and bringing Aspergillus PCR in line with
other molecular diagnostic assays (human immunodeﬁciency
virus, hepatitis C virus, or cytomegalovirus).
Quality Control
Neither GM-EIA nor BDG had QC schemes when incorporated
into EORTC/MSG deﬁnitions. Currently, external QC for
Aspergillus PCR can be independently determined by testing
the Quality Control for Molecular Diagnostics Aspergillus spe-
cies DNA panel. The EAPCRI has responded to user feedback
and is providing performance information for individual cen-
ters for QC purposes.
Clinical Validity
PCR Testing of Blood and BAL Samples: Clinical Consider-
ations. Although both blood and BAL ﬂuid are regularly test-
ed by PCR assays, their utility differs considerably. Clinical
evidence consistent with IA may prompt a diagnostic workup
involving BAL ﬂuid, which, if positive, would improve conﬁ-
dence in the diagnosis when assay speciﬁcity is high. Converse-
ly, the testing of multiple blood samples, as part of a screening
strategy, increases sensitivity sufﬁciently, such that consistently
negative tests results exclude disease. The 2 approaches are not
mutually exclusive and should be used to complement each
other, with frequent positivity during screening or clinical dete-
rioration prompting a diagnostic workup.
From a diagnostic perspective, the speciﬁcities of PCR BAL
testing were signiﬁcantly greater than when testing blood by
PCR (P < .0001; Table 3). Conversely, when screening, the sen-
sitivity when testing blood as determined by Mengoli et al [16]
was signiﬁcantly greater than BAL PCR (P = .0012–.015). This
was also true for the study of Arvanitis et al [19]when blood was
compared to the BAL ﬂuid study of Avni et al [18] (P = .02).
Comparison of PCR With Antigen Detection When Testing
Blood. Although the speciﬁcity of PCR (Table 3) was signiﬁ-
cantly lower (P < .0001) than was found for GM-EIA and BDG
before their inclusion into EORTC/MSG deﬁnitions (Table 2),
the PCR sensitivity, as determined by the study of Mengoli et al
[16] was signiﬁcantly higher than both GM-EIA (P = .048) and
BDG (P = .009). When comparing meta-analyses, the speciﬁcity
of both antigen tests remained signiﬁcantly higher than for PCR
(P < .0001–.012), whereas the sensitivity of PCR remained sig-
niﬁcantly higher than for BDG (P < .0001–.0477).
Comparison of PCR With Antigen Detection When Testing
BAL. There was no signiﬁcant difference in sensitivity (P =
.26–.38) or speciﬁcity (P = .74–.76) of PCR compared with
GM-EIA when testing BAL ﬂuid before inclusion into the
EORTC/MSG deﬁnitions. However, when comparing the meta-
analyses of both assays, PCR consistently had higher speciﬁcity
(P < .0001–.0019; Table 3).
Further Considerations. Aspergillus PCR testing using
methods consistent with the EAPCRI recommendations was
associated with signiﬁcantly greater speciﬁcity (98%) over non-
compliant protocols (85%), coupled with a trend toward
improved sensitivity (87%) for compliant over noncompliant
methods (82%), providing evidence for the beneﬁts of standard-
ization [19]. Further methodological standardization can be
achieved by automated testing of serum/plasma, providing per-
formance comparable to that of whole blood without complex
DNA extraction procedures [79].
False positivity is usually individual to that assay (for GM-
EIA and BDG, see Supplementary Table 1). Fungal PCR false
positivity has been associated with molecular biology reagents,
including manual and automated extraction platforms, but also
Vacutainer contamination, nutritional supplements, and respi-
ratory tract colonization [80–87]. Both false-positive and false-
negative results can occur through the use of inappropriately
designed oligonucleotides, particularly if these interact with
human DNA [67, 82]. Like other biomarker assays, false-negative
results can occur through the prior use of antifungal agents for
prophylaxis or therapy [88].
Assay Characteristics and Clinical Utility. Recently, a
multicenter randomized controlled trial comparing nonculture
diagnostics (GM-EIA/PCR) with culture and histology showed
that the nonculture arm improved diagnosis and signiﬁcantly
reduced the use of empiric antifungal therapy (17%; P = .002),
with no signiﬁcant effect on all-cause or fungal-related mortal-
ity. No cases of IAwere missed in the nonculture arm, providing
an effective strategy for managing IA [89]. In a further multi-
center randomized study, there was an earlier time to diagnosis,
reduced use of empirical antifungal therapy, and reduced
diagnoses of proven and probable IA, as well as improved fun-
gal-free survival using combined PCR/GM-EIA surveillance
compared with GM-EIA alone [90].
A reduction in unnecessary antifungal therapy was also
shown in a prospective cohort study evaluating routine noncul-
ture screening of 549 hematological patients [91]. Over a 5-year
period, antifungal expenditure was approximately halved.
The combined PCR/GM-EIA strategy had a sensitivity of
98.1%, and consistently negative tests could be used to exclude
IA (likelihood ratio of a negative test result, 0.04). If both tests
were positive on multiple occasions, a positive likelihood of
11.16 was highly suggestive of disease. Combining both tests
showed optimal clinical utility for the diagnosis and manage-
ment of IA.
With GM-EIA cross-reacting with other fungal species [20,
92], and BDG detecting a broad range of fungi, PCR is the
only non-culture-based assay that can be designed to identify As-
pergillus to a species level providing accurate epidemiology, and
identifying species that may prove resistant to antifungal drugs
(eg, amphotericin B vs Aspergillus terreus or Aspergillus lentulus).
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Azole resistance in A. fumigatus is also a potential clinical con-
cern; molecular-based assays can detect speciﬁc mutations that
confer resistance [73, 93]. Direct testing of a clinical sample will
improve sensitivity and reduce the time to result compared with
culture.
CONCLUSIONS
The development of methodological recommendations together
with commercially available assays allows PCR to be standard-
ized, and potentially associated with improved performance.
In terms of assuring the quality and consistency of assay per-
formance, only PCR has independently available control mate-
rial and international QC schemes to calibrate and allow
impartial comparison of different assays.
The diagnostic odds ratio for PCR is comparable to that for
GM-EIA and BDG. The speciﬁcity of BAL PCR is greater than
GM-EIA, providing better utility for a diagnostic test. When
testing serum, the sensitivity appears superior for PCR, making
it more suited to a screening strategy. Although sources of false
positivity and negativity may be peculiar to PCR, the associated
risks are similar to other biomarkers.
The revised EORTC/MSG deﬁnitions emphasize that the
only difference between probable IA and possible IA is the pres-
ence or absence of mycological evidence of Aspergillus. It is
therefore important that the analytical speciﬁcity of any assay
is sound. Currently, PCR is the only nonculture assay that has
the capability of being genus and species speciﬁc, and has the
added potential to determine azole resistance.
The use of a standardized PCRmay improve performance, and
recent evidence suggests that testing in combination with GM-
EIA may provide the optimal management strategy; future deﬁ-
nitions should emphasize this. A comprehensive evaluation of
PCR is required to overcome the limitations associated with
this current review of selected articles. A summary of the current
status of biomarker testing is shown in Table 5, and expands the
evidence base for antigen testing beyond the information limited
by preincorporation into the EORTC/MSG deﬁnitions. The in-
formation available for PCR is at least comparable to that for
other tests, and the signiﬁcance of PCR positivity should be in
line with other biomarkers. These ﬁndings are commended to
the wider fungal community to ultimately decide whether PCR
is sufﬁciently validated and standardized for inclusion in the
EORTC/MSG deﬁnitions of invasive fungal disease.
Table 5. Summary of Currently Available Assay Characteristics of Biomarker Assays Capable of Detecting Invasive Aspergillosis With an
Impact on Clinical Use
Characteristic GM-EIA to Date β-D-Glucan to Date PCR to Date
Methodological
recommendations
Single commercial
assay with SOP:
Platelia Aspergillus
antigen (BioRad)
Five different commercial assays available
utilizing different methods and materials:
Fungitell (Associates of Cape Cod)
Fungitec G-Test MK (Seikagaku Corporation)
B-G Star (Maruha Corporation) (limited clinical
validation reported)
B-Glucan Test Wako (Wako Pure Chemicals)
Dynamiker Fungus (1–3)-β-D-Glucan Assay
(Dynamiker Biotechnology (Tianjin) Co, Ltd
(limited clinical validation reported)
Several commercial assays:
Pathonostics Aspergenius
Roche Septifast
Myconostica MycAssay
Ademtech Mycogenie
Renishaw Fungiplex
Procedural recommendations for
DNA extraction (EAPCRI)
Control material Controls supplied by the
manufacturer
No independent
material available
Controls supplied by the manufacturer
No independent material available
Controls supplied by the
manufacturer
International DNA calibrator available
Quality control Internal – BioRad
Proficiency panel
No Independent – QCMD and EAPCRI
panels
Sensitivity rangea, % Blood: 79.3
BAL: 83.6–85.7
Blood: IA: 56.8–77.1 Blood: 84–88
BAL: 76.8–79.6
Specificity rangea, % Blood: 80.5–86.3
BAL: 89.0–89.4
Blood: 81.3–97.0 Blood: 75–76
BAL: 93.7–94.5
False positives Yes Yes Yes
False negatives Yes Yes Yes
Clinical utility Yesb,c,d No Yesb,c,d
Abbreviations: BAL, bronchoalveolar lavage; EAPCRI, European Aspergillus PCR initiative; GM-EIA, galactomannan enzyme immunoassay; PCR, polymerase chain
reaction; QCMD, Quality Control for Molecular Diagnostics; SOP, standard operating procedure.
a Range determined from results presented in the relevant meta-analyses (see Table 3).
b Morrissey et al [89].
c Aguado et al [90].
d Barnes et al [91].
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Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Note
Potential conﬂicts of interest. P. L. W. is a founding member of the Eu-
ropean Aspergillus PCR Initiative (EAPCRI); received project funding from
Myconostica, Luminex, and Renishaw Diagnostics; was sponsored by Myco-
nostica, MSD, and Gilead Sciences to attend international meetings; and pro-
vided consultancy for Renishaw Diagnostics Limited. J. R. W. has received
speaker fees from Pﬁzer and has provided consultancy for Merck, Astellas,
Ansun andGilead. S. B. is a founding member of the EAPCRI, received project
funding from Renishaw Diagnostics, was sponsored by Pﬁzer and MSD to at-
tend international meetings, and provided consultancy for Gilead. J. L. is a
founding member of the EAPCRI, received an educational grant and scientiﬁc
fellowship award from Pﬁzer, and was sponsored by Astellas to attend inter-
national meetings. T. F. P. has received research grants from Astellas and
Merck, and has been a consultant or scientiﬁc advisory board member for As-
tellas, Merck, Scynexis, Toyoma, and Viamet. M. A. S. has been a member of
advisory boards for and received research funding from Pﬁzer, MSD, Scher-
ing-Plough, and Gilead Sciences; serves on the Antifungal Advisory Boards of
Gilead Sciences Inc, MSD, and Pﬁzer; and has received funding in the form of
untied grants from Gilead Sciences Inc, MSD Australia, and Pﬁzer
Australia. R. A. B. is a founding member of the EAPCRI, received an educa-
tional grant and scientiﬁc fellowship award from Gilead Sciences and Pﬁzer, is
a member of the advisory board and speakers’ bureau for Gilead Sciences,
MSD, Astellas, and Pﬁzer, and was sponsored by Gilead Sciences and Pﬁzer
to attend international meetings. P. G. P. has received research support from
Astellas, Merck, Gilead, Scynexis, and T2 Biosystems; and has served as an ad
hoc scientiﬁc advisor for Astellas, Merck, Gilead, Scynexis, T2 Biosystems, and
Viamet. J. P. D. is a founding member of the EAPCRI, is a member of the ad-
visory board for Gilead Sciences and Pﬁzer, and has been on speakers’ bureaus
for Gilead Sciences, MSD, and Pﬁzer.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Ascioglu S, Rex JH, de Pauw B, et al. Deﬁning opportunistic invasive
fungal infections in immunocompromised patients with cancer and he-
matopoietic stem cell transplants: an international consensus. Clin In-
fect Dis 2002; 34:7–14.
2. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised deﬁnitions of invasive
fungal disease from the European Organization for Research and Treat-
ment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:
1813–21.
3. Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan,
beta-d-glucan, Aspergillus lateral-ﬂow device, conventional culture,
and PCR tests with bronchoalveolar lavage ﬂuid for diagnosis of inva-
sive pulmonary aspergillosis. J Clin Microbiol 2014; 52:2039–45.
4. White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time PCR,
galactomannan enzyme-linked immunosorbent assay (ELISA), and a
novel lateral-ﬂow device for diagnosis of invasive aspergillosis. J Clin
Microbiol 2013; 51:1510–6.
5. Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of
detecting galactomannan in bronchoalveolar lavage ﬂuid for diagnosing
invasive aspergillosis. PLoS One 2012; 7:e43347.
6. Guo Y-L, Chen Y-Q, Wang K, et al. Accuracy of BAL galactomannan in
diagnosing invasive aspergillosis. Chest 2010; 138:817–24.
7. Leeﬂang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan
detection for invasive aspergillosis in immunocompromized patients.
Cochrane Database Syst Rev 2009; 8:CD007394.
8. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a
galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417–27.
9. Lamoth F, Cruciani M, Mengoli C, et al. B-Glucan antigenemia assay
for the diagnosis of invasive fungal infections in patients with haemato-
logical malignancies: a systematic review and meta-analysis of cohort
studies from the Third European Conference on Infections in Leukae-
mia (ECIL-3). Clin Infect Dis 2012; 54:633–43.
10. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A,
Rafailidis PI, Falagas ME. β-D-glucan assay for the diagnosis of invasive
fungal infections: a meta-analysis. Clin Infect Dis 2011; 52:750–70.
11. He S, Hang J-P, Zhang L, et al. A systematic review and meta-analysis
of diagnostic accuracy of serum 1,3-B-D-glucan for invasive fungal in-
fection: focus on cutoff levels. J Microbiol Immun Infect 2014;
48:351–61.
12. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum
1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidi-
asis, and invasive aspergillosis: systematic review and meta-analysis.
J Clin Microbiol 2012; 50:7–15.
13. Tang CM, Holden DW, Aufauvre-Brown A, Cohen J. The detection of
Aspergillus spp. by the polymerase chain reaction and its evaluation in
bronchoalveolar lavage ﬂuid. Am Rev Respir Dis 1993; 148:1313–7.
14. White PL, Barnes RA. Aspergillus PCR. In: Latge J-P, SteinbachWJ, eds.
Aspergillus fumigatus and aspergillosis. 1st ed. Washington, DC: ASM
Press, 2009:373–88.
15. Tuon FF. A systematic literature review on the diagnosis of invasive as-
pergillosis using the polymerase chain reaction (PCR) from bronchoal-
veolar lavage clinical samples. Rev Iberoam Micol 2007; 24:89–94.
16. Mengoli C, Cruciani M, Barnes RA, Loefﬂer J, Donnelly JP. Use of PCR
for diagnosis of invasive aspergillosis: systematic review of and meta-
analysis. Lancet Infect Dis 2009; 9:89–96.
17. Sun W, Wang K, Gao W, et al. Evaluation of PCR on bronchoalveolar
lavage ﬂuid for diagnosis of invasive aspergillosis: a bivariate meta-anal-
ysis and systematic review. PLoS One 2011; 6:e28467.
18. Avni T, Levy I, Sprecher H, Yahav D, Leibovici L, Paul M. Diagnostic
accuracy of PCR alone compared to galactomannan in bronchoalveolar
lavage ﬂuid for diagnosis of invasive pulmonary aspergillosis: a system-
atic review. J Clin Microbiol 2012; 50:3652–8.
19. Arvanitis M, Ziakas PD, Zacharioudakis IM, Zervou FN, Caliendo AM,
Mylonakis E. PCR in diagnosis of invasive aspergillosis: a meta-analysis
of diagnostic performance. J Clin Microbiol 2014; 52:3731–42.
20. Swannink CMA, Meis JFGM, Rijs AJMM, Donnelly JP, Verweij PE.
Speciﬁcity of a sandwich enzyme-linked immunosorbent assay for de-
tecting Aspergillus galactomannan. J Clin Microbiol 1997; 35:257–60.
21. Verweij PE, Erjavec Z, Sluiters W, et al. Detection of antigen in sera of
patients with invasive aspergillosis: intra and interlaboratory reproduc-
ibility. J Clin Microbiol 1998; 36:1612–6.
22. Bretagne S, Marmorat-Khuoung A, KuentzM, Latge J-P, Bart-Delabesse
E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by
sandwich ELISA: practical use in neutropenic patients. J Infect 1997;
35:7–15.
23. Maertens J, Vernhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screen-
ing for circulating galactomannan as non-invasive diagnostic tool for
invasive aspergillosis in prolonged neutropenic patients and stem cell
transplantation recipients a prospective validation. Blood 2001; 97:
1604–10.
24. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy controlled pro-
spective evaluation of serial screening for circulatory galactomannan by
a sandwich enzyme linked immunosorbent assay for haematological pa-
tients at risk of invasive aspergillosis. J Clin Microbiol 1999; 37:3223–8.
25. Sulahian A, Boutboul F, Ribaud P, Leblanc T, Lacroix C, Derouin F.
Value of antigen detection using an enzyme immunoassay in the
Aspergillus PCR and Antigen Testing • CID 2015:61 (15 October) • 1301
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/61/8/1293/376768 by guest on 13 M
arch 2019
diagnosis and prediction of invasive aspergillosis in two adult and pe-
diatric hematology units during a 4 year prospective study. Cancer
2001; 91:311–8.
26. Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme im-
munoassay and latex agglutination test for detection of galactomannan
in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis
1996; 15:139–45.
27. Machetti M, Feasi M, Mordini N, et al. Comparison of an enzyme im-
munoassay and a latex agglutination system for the diagnosis of invasive
aspergillosis in bone marrow transplant recipients. BMT 1998; 21:
917–21.
28. Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergil-
lus galactomannan antigenemia for invasive aspergillosis by enzyme
linked immunosrobent assay in neutropenic patients treated for haema-
tological malignancies. Hematol J 2000; 1:111–6.
29. Patterson JE, Zidouh A, Miniter P, Andriole VT, Patterson TF. Hospital
epidemiologic surveillance for invasive aspergillosis: patient demo-
graphics and the utility of antigen detection. Infect Cont Hosp Epide-
miol 1997; 18: 104–8.
30. Williamson ECM, Oliver DA, Johnson EM, Foot ABM, Marks DI,
Warnock DW. Aspergillus antigen testing in bone marrow transplant
recipients. J Clin Pathol 2000; 53:362–6.
31. Sieman M, Koch-Dorﬂer M. The Platelia Aspergillus ELISA in diagnosis
of invasive pulmonary aspergillosis (IPA). Mycoses 2001; 44:266–72.
32. Fleck E, Rabaud C, Beot S, et al. Invasive aspergillosis in AIDS patients.
Med Maladies Infect 1999; 29:401–6.
33. Herrmann J, Gugel A, Freidank H, Bertz H, Finke J. Aspergillus antigen
detection: comparison of a new sandwich ELISA with the latex aggluti-
nation test in patients with histologically proven invasive aspergillosis.
Mycoses 1998; 41(suppl 1):83–5.
34. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples
for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33:1504–12.
35. Kami M, Ogawa S, Kanda Y, et al. Early diagnosis of central nervous
system aspergillosis using polymerase chain reaction, latex agglutination
test, and enzyme linked immunosorbent assay. Brit J Haem 1999; 106:
536–7.
36. Salonen J, Lehtonen OP, Terasarvi MR, Nikoskelainen J. Aspergillus an-
tigen in serum urine and bronchoalveolar lavage specimens of neutro-
penic patients in relation to clinical outcome. Scand J Infect Dis 2000;
32:485–90.
37. Bretagne S, Costa J-M, Bart-Delanesse E, Dhedin N, Rieux C, Cordon-
nier C. Comparison of serum galactomannan antigen detection and
competitive polymerase chain reaction for diagnosing invasive aspergil-
losis. Clin Infect Dis 1998; 26:1407–12.
38. Stynen D, Goris A, Sarfati J, Latge J-P. A new sensitive sandwich enzyme
linked immunosorbent assay to detect galactofuran in patients with in-
vasive aspergillosis. J Clin Microbiol 1995; 33:497–500.
39. Fortun J, Martin-Davila P, Alvarez ME, et al. Aspergillus antigenemia
sandwich enzyme immunoassay test as a serodiagnostic method for in-
vasive aspergillosis in liver transplant recipients. Transplantation 2001;
71:145–9.
40. Sieman M, Koch-Dorﬂer M, Gaude M. False positive results in prema-
ture infants with the Platelia Aspergillus sandwich enzyme linked im-
munosorbent assay. Mycoses 1998; 41:373–7.
41. Verweij PE, Stynen D, Rijs AJ, et al. Sandwich enzyme linked immuno-
sorbent assay compared to latex agglutination test for diagnosing inva-
sive aspergillosis in immunocompromised patients. J Clin Microbiol
1995; 33:1912–4.
42. Verweij PE, Latge J-P, Rijs AJ, et al. Comparison of antigen detection
and PCR assay using bronchoalveolar lavage ﬂuid for diagnosing inva-
sive pulmonary aspergillosis in patients receiving treatment for haema-
tological malignancies. J Clin Microbiol 1995; 33:3150–3.
43. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-
linked immunosorbent assay for serum galactomannan: early predictive
value and clinical use in invasive aspergillosis. Pediatr Infect Dis 1996;
15:232–7.
44. Tabone M-D, Vu-Thien H, Latge J-P, et al. Value of galactomannan de-
tection by sandwich enzyme linked immunosorbent assay in the early
diagnosis and follow-up of invasive aspergillosis. Opportunistic Patho-
gens 1997; 9:7–13.
45. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. Aspergillus
meningitis: diagnosis by non-culture based microbiological methods
and management. J Clin Microbiol 1999; 37:1186–9.
46. Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF.
Serial monitoring of Aspergillus antigen in the early diagnosis of
invasive aspergillosis. Preliminary investigations with two examples.
Infection 1997; 25:86–9.
47. Machetti M, Zotti M, Veroni L, et al. Antigen detection in the diagnosis
and management of a patient with probable cerebral aspergillosis treat-
ed with voriconazole. Transpl Infect Dis 2000; 2:140–4.
48. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan an-
tigen in the cerebrospinal ﬂuid of bone marrow transplant recipients
with probable cerebral aspergillosis. J Clin Microbiol 2002; 40:1496–9.
49. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan
detection in the diagnosis of invasive aspergillosis in cancer patients.
J Clin Oncol 2002; 20:1898–906.
50. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ.
Detection of galactomannan antigenemia by enzyme immunoassay for
the diagnosis of invasive aspergillosis: variables that affect performance.
J Infect Dis 2004; 190:641–9.
51. D’Haese J, Theunissen K, Vermeulen E, et al. Detection of galacto-
mannan in bronchoalveolar lavage ﬂuid samples of patients at risk
for invasive pulmonary aspergillosis: analytical and clinical validity.
J Clin Microbiol 2012; 50:1258–63.
52. Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij
PE. In vitro release by Aspergillus fumigatus of galactofuranose antigens,
1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of
invasive aspergillosis. J Clin Microbiol 2006; 44:1711–8.
53. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical
evaluation of the 1–3 B-D-glucan assay as an aid to diagnosis of fungal
infections in humans. Clin Infect Dis 2005; 41:654–9.
54. Pickering JW, Sant HW, Bowles CAP, Roberts WL, Woods GL. Evalu-
ation of 1–3 B-D-glucan assay for the diagnosis of invasive fungal infec-
tions. J Clin Microbiol 2005; 43:5957–62.
55. Odabasi Z, Mattiuzzi G, Estey E, et al. B-D-glucan as a diagnostic ad-
junct for invasive fungal infections: validation, cut-off development, and
performance in patients with acute myelogenous leukemia and myelo-
dysplastic syndrome. Clin Infect Dis 2004; 39:199–205.
56. Tanaka S, Aketagawa J, Takahashi S, et al. Inhibition of high-molecular-
weight-(1–3)-beta-D-glucan-dependent activation of a limulus coagula-
tion factor G by laminaran oligosaccharides and curdlan degradation
products. Carbohydr Res 1993; 244:115–27.
57. Pazos C, Ponton J, Del Palacio A. Contribution of 1–3 B-D-glucan
chromogenic assay to diagnose therapeutic monitoring of invasive as-
pergillosis in neutropenic adult patients: a comparison with serial
screening with circulating galactomannan. J Clin Microbiol 2005; 43:
299–305.
58. Mori T, Ikemoto H, Matsumura M, et al. Evaluation of plasma (1–3)-
beta-D-glucan measurement by the kinetic turbidimetric limulus test,
for the clinical diagnosis of mycotic infections. Eur J Clin Chem Clin
Biochem 1997; 35:553–60.
59. Mitsutake K, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan an-
tigen, Cand-tec antigen, and beta-glucan in patients with candidaemia.
J Clin Microbiol 1996; 34:1918–21.
60. Mori T, Matsumura M. Clinical evaluation of diagnostic methods using
plasma and/or serum for three mycoses. Jpn J Med Mycol 1999; 40:
223–30.
61. Akamatsu N, Sugawara Y, Kaneko J, Tamura S, Makuuchi M. Pre-
emptive treatment of fungal infection based on the plasma (1–3)
B-D-glucan levels after liver transplantation. Infection 2007; 35:346–51.
62. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the
chest, latex agglutination test and plasma (1–3) B-D-glucan assay in
1302 • CID 2015:61 (15 October) • White et al
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/61/8/1293/376768 by guest on 13 M
arch 2019
early diagnosis of invasive pulmonary aspergillosis: a prospective study
of 215 patients. Haematologica 2000; 85:745–52.
63. Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the
diagnostic potential of real-time PCR, double sandwich enzyme linked
immunosorbent assay for galactomannan, and a (1–3)-B-D-glucan test
in weekly screening for invasive aspergillosis in patients with haemato-
logical disorders. J Clin Microbiol 2004; 42:2733–41.
64. Miyazaki T, Kohno S, Mitsuake K, et al. Plasma (1–3) beta-D-glucan
and fungal antigenemia in patients with candidemia, aspergillosis and
cryptococcosis. J Clin Microbiol 1995; 33:3115–8.
65. Obayashi T, Yoshida M, Mori T, et al. Plasma (1–3) B-D-glucan mea-
surement in diagnosis of invasive deep mycosis and fungal febrile epi-
sodes. Lancet 1995; 345:17–20.
66. Metan G, Koc AN, Atalay A, et al. What should be the optimal cut-off of
serum B-D-glucan for the detection of invasive pulmonary aspergillosis
in patients with haematological malignancies. Scand J Infect Dis 2012;
44:330–6.
67. White PL, Barton R, Guiver M, et al. A consensus on fungal polymerase
chain reaction diagnosis? A United Kingdom-Ireland evaluation of
polymerase chain reaction methods for detection of systemic fungal
infections. J Mol Diagn 2006; 8:376–84.
68. Reichard U, Buchheidt D, Lass-Flörl C, et al. Inter-laboratory compar-
ison of PCR-based identiﬁcation of Candida and Aspergillus DNA in
spiked blood samples. Mycoses 2012; 55:426–34.
69. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step clos-
er to standardization. J Clin Microbiol 2010; 48:1231–40.
70. White PL, Mengoli C, Bretagne S, et al. Evaluation of Aspergillus PCR
protocols for testing serum specimens. J Clin Microbiol 2011; 49:
3842–8.
71. White PL. The European Aspergillus PCR Initiative (EAPCRI)—where
do we stand? [abstract W12.2] In: 6th Trends in Medical Mycology con-
ference, Copenhagen, Denmark, 11–14 October 2013.
72. White PL, Perry MD, Moody A, Follett SA, Morgan G, Barnes RA. Eval-
uation of analytical and preliminary clinical performance of Myconos-
tica MycAssay Aspergillus when testing serum specimens for diagnosis
of invasive aspergillosis. J Clin Microbiol 2011; 49:2169–74.
73. White PL, Hibbitts SJ, Perry MD, et al. Evaluation of a commercially
developed semi-automated PCR-SERS assay for the diagnosis of inva-
sive fungal disease. J Clin Microbiol 2014; 52:3536–43.
74. Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergil-
losis by a commercial real-time PCR assay for Aspergillus DNA in
bronchoalveolar lavage ﬂuid samples from high-risk patients compared
to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49:
4273–8.
75. Chong GL, van de SandeWW, Dingemans GJ, et al. Validation of a new
Aspergillus real-time PCR assay for direct detection of Aspergillus and
azole resistance of Aspergillus fumigatus on bronchoalveolar lavage
ﬂuid. J Clin Microbiol 2015; 53:868–74.
76. Lovari R, Metzgar D, Toleno D, et al. Characterisation of a PCR/ESI-MS
assay for detection and identiﬁcation of diverse fungi in bronchoalveo-
lar lavage samples [abstract O219]. In: European Congress of Clinical
Microbiology and Infectious Diseases, 2014.
77. Chang SS, Hsieh WH, Liu TS, et al. Multiplex PCR system for rapid
detection of pathogens in patients with presumed sepsis—a systemic re-
view and meta-analysis. PLoS One 2013; 8:e62323.
78. Lyon GM, Abdul-Ali D, Loefﬂer J, et al. Development and evaluation of
a calibrator material for nucleic acid-based assays for diagnosing asper-
gillosis. J Clin Microbiol 2013; 51:2403–5.
79. Springer J, Morton CO, Perry M, et al. Multicenter comparison
of serum and whole-blood specimens for detection of Aspergillus
DNA in high-risk hematological patients. J Clin Microbiol 2013; 51:
1445–50.
80. Rimek D, Garg AP, HaasWH, Kappe R. Identiﬁcation of contaminating
fungal DNA sequences in Zymolyase. J Clin Microbiol 1999; 37:830–1.
81. Loefﬂer J, Hebart H, Bialek R, et al. Contaminations occurring in fungal
PCR assays. J Clin Microbiol 1999; 7:1200–2.
82. White PL, Barnes RA. Aspergillus PCR—platforms, strengths and
weaknesses. Med Mycol 2006; 44(suppl):191–8.
83. Jaeger EE, Carroll NM, Choudhury S, et al. Rapid detection and iden-
tiﬁcation of Candida, Aspergillus, and Fusarium species in ocular
samples using nested PCR. J Clin Microbiol 2000; 38:2902–8.
84. Perry MD,White PL, Barnes RA. Comparison of four automated nucle-
ic acid extraction platforms for the recovery of DNA from Aspergillus
fumigatus. J Med Microbiol 2014; 63:1160–6.
85. Harrison E, Stalhberger T, Whelan R, et al. Aspergillus DNA contami-
nation in blood collection tubes. Diagn Microbiol Infect Dis 2010;
67:392–4.
86. Bretagne S, Costa JM, Marmorat-Khuong A, et al. Detection of Asper-
gillus species DNA in bronchoalveolar lavage samples by competitive
PCR. J Clin Microbiol 1995; 33:1164–8.
87. Millon L, Grenouillet F, Crouzet J, et al. False positive Aspergillus real-
time PCR assay due to a nutritional supplement in a bone marrow
transplant recipient with GVH disease. Med Mycol 2010; 48:661–4.
88. Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillo-
sis during antifungal therapy by PCR analysis of blood samples. J Clin
Microbiol 2004; 42:4154–7.
89. Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR
versus culture and histology for directing use of antifungal treatment
for invasive aspergillosis in high-risk haematology patients: a rando-
mised controlled trial. Lancet Infect Dis 2013; 13:519–28.
90. Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, et al. Serum
galactomannan versus a combination of galactomannan and PCR-based
Aspergillus DNA detection for early therapy of invasive aspergillosis in
high-risk hematological patients: a randomized controlled trial. Clin
Infect Dis 2014; 60:405–14.
91. Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention
and diagnosis of invasive fungal disease in high-risk patients within an
integrative care pathway. J Infect 2013; 67:206–14.
92. Cummings JR, Jamison GR, Boudreaux JW, et al. Cross reactivity of
non-aspergillus fungal species in the Aspergillus galactomannan
enzyme immunoassay. Diagn Microbiol Infect Dis 2007; 59:113–5.
93. Van der Linden JW, Snelders E, Arends JP, et al. Rapid diagnosis of
azole resistant aspergillosis by direct PCR using tissue specimens.
J Clin Microbiol 2010; 48:1478–80.
Aspergillus PCR and Antigen Testing • CID 2015:61 (15 October) • 1303
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article-abstract/61/8/1293/376768 by guest on 13 M
arch 2019
